All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
51 - 60 of 102 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Presentation
Real-world characterization of HER2-altered NSCLC patients who received second-line therapy in Japan
Author(s): Uehara et al.
Phase Ia results for systemic STING agonist BI 1703880 plus ezabenlimab in patients with advanced solid tumors: progress to date
Author(s): Parkes et al.
DAREON®-8: A Phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC)
Author(s): Peters et al.
Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion™ LUNG-1
Author(s): Popat et al.
Effects of zongertinib on dabigatran, rosuvastatin, metformin, and furosemide PK
Author(s): Funck et et al.
Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: results from an ongoing Phase I trial
Author(s): Capdevila et al.
An open-label, Phase Ib trial of the SIRPα inhibitor BI 765063 in combination with the PD-1 inhibitor ezabenlimab and cetuximab in patients with head and neck squamous cell carcinoma
Author(s): Rojas et al.
An open-label, Phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors
Author(s): Wang et al.
Zongertinib in Patients with Previously Treated HER2-mutant Advanced NSCLC: Beamion™ LUNG-1
Author(s): Heymach et al.
Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of Beamion™ LUNG-1
Author(s): Yoh et al.